Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 23452174)

1.

Cinacalcet hydrochloride for the treatment of hyperparathyroidism.

Verheyen N, Pilz S, Eller K, Kienreich K, Fahrleitner-Pammer A, Pieske B, Ritz E, Tomaschitz A.

Expert Opin Pharmacother. 2013 Apr;14(6):793-806. doi: 10.1517/14656566.2013.777041. Epub 2013 Mar 4. Review.

PMID:
23452174
2.

Presumed osteosarcoma.

Kettritz R, Mohebbi N, Claus T, Kettritz U, Schneider W, Luft FC.

Clin Kidney J. 2013 Jun;6(3):338-40. doi: 10.1093/ckj/sft040. Epub 2013 May 3. No abstract available.

3.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2015 Jun 4. doi: 10.1038/jhh.2015.56. [Epub ahead of print]

PMID:
26040438
4.

Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.

Mingione A, Verdelli C, Terranegra A, Soldati L, Corbetta S.

Curr Cancer Drug Targets. 2015 Jun 2. [Epub ahead of print]

PMID:
26033088
5.
6.

The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.

Lorenzoni V, Trieste L, Turchetti G.

Expert Rev Pharmacoecon Outcomes Res. 2015 May 17:1-14. [Epub ahead of print]

PMID:
25988877
7.

Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics.

Cunningham J, Floege J, London G, Rodriguez M, Shanahan CM.

NDT Plus. 2008 Jan;1(Suppl 1):i29-i35. doi: 10.1093/ndtplus/sfm042.

8.

Spinal cord compression from a brown tumour despite maximal medical therapy with cinacalcet and sevelamer.

Wiebe C, Ho J, Cohen B, Bohm C.

NDT Plus. 2008 Jun;1(3):151-3. doi: 10.1093/ndtplus/sfn016. Epub 2008 Mar 3. No abstract available.

9.

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS.

Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17.

10.

Lag-censoring analysis: lights and shades.

Tripepi G, Heinze G, Jager KJ, Stel VS, Dekker FW, Zoccali C.

Nephrol Dial Transplant. 2015 May;30(5):700-5. doi: 10.1093/ndt/gfv068. Epub 2015 Apr 16.

PMID:
25883199
11.

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.

Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, Trotman ML, Dehmel B, Chertow GM.

Pharm Stat. 2015 May;14(3):242-51. doi: 10.1002/pst.1680. Epub 2015 Apr 6.

PMID:
25851955
12.

Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study.

Brardi S, Cevenini G, Verdacchi T, Romano G, Ponchietti R.

Arch Ital Urol Androl. 2015 Mar 31;87(1):66-71. doi: 10.4081/aiua.2015.1.66.

PMID:
25847900
13.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

14.

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.

PMID:
25505257
15.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators.

J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363.

16.

Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.

Marotta V, Di Somma C, Rubino M, Sciammarella C, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Modica R, Vitale M, Colao A, Faggiano A.

Endocrine. 2015 May;49(1):274-8. doi: 10.1007/s12020-014-0381-0. Epub 2014 Aug 15. No abstract available.

PMID:
25123977
17.

What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results.

Locatelli F, Messa P, Bellasi A, Cozzolino M, Di Luca M, Garibotto G, Gesualdo L, Malberti F, Massimetti C, Mazzaferro S, Mereu MC, Morosetti M, Morrone LF, Panuccio V, Rapisarda F, Russo D, Schinella D.

G Ital Nefrol. 2013 Sep-Oct;30(5). pii: gin/30.5.4.

18.

Cinacalcet ameliorates cardiac fibrosis in uremic hearts through suppression of endothelial-to-mesenchymal transition.

Wu M, Tang RN, Liu H, Pan MM, Lv LL, Zhang JD, Crowley SD, Liu BC.

Int J Cardiol. 2014 Feb 15;171(3):e65-9. doi: 10.1016/j.ijcard.2013.11.105. Epub 2013 Dec 7. No abstract available.

PMID:
24382406
19.

Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A.

Minerva Endocrinol. 2013 Dec;38(4):389-94.

PMID:
24285106
20.

The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.

Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG.

J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9.

PMID:
24108314
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk